File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Ovarian failure and flares of systemic lupus erythematosus

TitleOvarian failure and flares of systemic lupus erythematosus
Authors
Issue Date1999
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0004-3591/
Citation
Arthritis And Rheumatism, 1999, v. 42 n. 6, p. 1274-1280 How to Cite?
AbstractObjective. To study the effects of ovarian failure on disease flares in systemic lupus erythematosus (SLE). Methods. Fifty-four female premenopausal SLE patients who were under the age of 45 years and treated with continuous oral cyclophosphamide (CYC) for no more than 12 months were studied. All patients had been followed up for > 5 years following CYC treatment. Demographic characteristics, clinical and serologic profiles, and information concerning disease flares were recorded. Comparison of the number of severe and mild/moderate flares during the first 5 years after CYC treatment was made between patients who developed CYC-induced ovarian failure and those who did not. Results. Fourteen SLE patients had documented ovarian failure with hypoestrogenemia within 2 years after CYC treatment. Compared with the menstruating group of patients, those who developed ovarian failure were significantly older at the time of CYC therapy (mean 37.9 versus 25.5 years; P < 0.001), but otherwise no significant differences in organ manifestations and autoantibody profiles between the 2 groups were observed. Both the ovarian failure group and menstruating group of patients had similar SLE Disease Activity Index scores at the time of CYC treatment (mean 15.6 versus 17.7; P = 0.16), and had comparable treatment durations (mean 8.2 versus 7.8 months; P = 0.68) and cumulative doses of CYC (mean 20.4 versus 17.9 grams; P = 0.34). Flares of SLE were uncommon during the first year following CYC administration. However, during the 5-year followup period, patients who developed CYC-induced ovarian failure had significantly fewer severe flares (mean 0.014 versus 0.075 flares/patientyear; P = 0.01) and smaller total number of flares (mean 0.128 versus 0.250 flares/patient-year; P = 0.03) when compared with those who were still menstruating. Conclusion. This study provides an important clinical observation to support the notion that ovarian failure with hypoestrogenemia is protective against lupus flares and emphasizes the importance of estrogen status in the determination of disease activity in SLE.
Persistent Identifierhttp://hdl.handle.net/10722/162340
ISSN
2015 Impact Factor: 8.955
2015 SCImago Journal Rankings: 3.206
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorMok, CCen_US
dc.contributor.authorWong, RWSen_US
dc.contributor.authorLau, CSen_US
dc.date.accessioned2012-09-05T05:19:07Z-
dc.date.available2012-09-05T05:19:07Z-
dc.date.issued1999en_US
dc.identifier.citationArthritis And Rheumatism, 1999, v. 42 n. 6, p. 1274-1280en_US
dc.identifier.issn0004-3591en_US
dc.identifier.urihttp://hdl.handle.net/10722/162340-
dc.description.abstractObjective. To study the effects of ovarian failure on disease flares in systemic lupus erythematosus (SLE). Methods. Fifty-four female premenopausal SLE patients who were under the age of 45 years and treated with continuous oral cyclophosphamide (CYC) for no more than 12 months were studied. All patients had been followed up for > 5 years following CYC treatment. Demographic characteristics, clinical and serologic profiles, and information concerning disease flares were recorded. Comparison of the number of severe and mild/moderate flares during the first 5 years after CYC treatment was made between patients who developed CYC-induced ovarian failure and those who did not. Results. Fourteen SLE patients had documented ovarian failure with hypoestrogenemia within 2 years after CYC treatment. Compared with the menstruating group of patients, those who developed ovarian failure were significantly older at the time of CYC therapy (mean 37.9 versus 25.5 years; P < 0.001), but otherwise no significant differences in organ manifestations and autoantibody profiles between the 2 groups were observed. Both the ovarian failure group and menstruating group of patients had similar SLE Disease Activity Index scores at the time of CYC treatment (mean 15.6 versus 17.7; P = 0.16), and had comparable treatment durations (mean 8.2 versus 7.8 months; P = 0.68) and cumulative doses of CYC (mean 20.4 versus 17.9 grams; P = 0.34). Flares of SLE were uncommon during the first year following CYC administration. However, during the 5-year followup period, patients who developed CYC-induced ovarian failure had significantly fewer severe flares (mean 0.014 versus 0.075 flares/patientyear; P = 0.01) and smaller total number of flares (mean 0.128 versus 0.250 flares/patient-year; P = 0.03) when compared with those who were still menstruating. Conclusion. This study provides an important clinical observation to support the notion that ovarian failure with hypoestrogenemia is protective against lupus flares and emphasizes the importance of estrogen status in the determination of disease activity in SLE.en_US
dc.languageengen_US
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.interscience.wiley.com/jpages/0004-3591/en_US
dc.relation.ispartofArthritis and Rheumatismen_US
dc.subject.meshAdulten_US
dc.subject.meshCyclophosphamide - Adverse Effectsen_US
dc.subject.meshDisease Progressionen_US
dc.subject.meshEstradiol - Blooden_US
dc.subject.meshFemaleen_US
dc.subject.meshFollicle Stimulating Hormone - Blooden_US
dc.subject.meshHumansen_US
dc.subject.meshLupus Erythematosus, Systemic - Blood - Physiopathologyen_US
dc.subject.meshLuteinizing Hormone - Blooden_US
dc.subject.meshMenstruationen_US
dc.subject.meshPremenopauseen_US
dc.subject.meshPrimary Ovarian Insufficiency - Blood - Chemically Induced - Physiopathologyen_US
dc.subject.meshRetrospective Studiesen_US
dc.subject.meshSeverity Of Illness Indexen_US
dc.titleOvarian failure and flares of systemic lupus erythematosusen_US
dc.typeArticleen_US
dc.identifier.emailLau, CS:cslau@hku.hken_US
dc.identifier.authorityLau, CS=rp01348en_US
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.doi10.1002/1529-0131(199906)42:6<1274::AID-ANR26>3.0.CO;2-Ben_US
dc.identifier.pmid10366122-
dc.identifier.scopuseid_2-s2.0-0033040843en_US
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0033040843&selection=ref&src=s&origin=recordpageen_US
dc.identifier.volume42en_US
dc.identifier.issue6en_US
dc.identifier.spage1274en_US
dc.identifier.epage1280en_US
dc.identifier.isiWOS:000080786000026-
dc.publisher.placeUnited Statesen_US
dc.identifier.scopusauthoridMok, CC=34668219600en_US
dc.identifier.scopusauthoridWong, RWS=34875928200en_US
dc.identifier.scopusauthoridLau, CS=14035682100en_US

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats